The present invention generally relates to the detection, treatment or prevention of disease states. Specifically, the present invention relates to the detection, treatment or prevention of amyloidosis or amyloid-associated diseases. The present invention further comprises methods and compositions comprising therapeutic vaccines, antisera and molecular constructs, comprising expression vectors and fusion proteins encoded therein.

The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by:
(LF-s-Y)n or (Y-s-LF)n
[wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.

The present invention aims to provide a lactoferrin fusion protein, which is configured to retain the biological activities of natural lactoferrin, to have a significantly prolonged in vivo lifetime, and to be more clinically useful than natural and gene recombinant lactoferrin, as well as a method for preparation thereof, etc. The present invention provides a fusion protein formed with a protein or peptide comprising an FcRn-binding region and lactoferrin or a biologically active fragment or peptide of lactoferrin, which is represented by:
(LF-s-Y)n or (Y-s-LF)n
[wherein LF represents lactoferrin or a biologically active fragment or peptide of lactoferrin, represents the protein or peptide comprising an FcRn-binding region, s represents ally amino acid sequence of 0 to 10 residues, and n represents an integer of 1 to 10], or a variant thereof.

The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.

The present invention relates to a p75NTR neurotrophin binding protein, p75NTR(NBP), for use in the treatment of pain and/or a symptom of pain.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7EIX.sub.10X.sub.11LPNLX.sub.16RX.sub.18QYX.sub.21AFIX.sub.25X.sub.26LX.sub.28D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-1 receptor type-I (IL-1R-I) which comprise the binding motif (BM) EX.sub.2X.sub.3X.sub.4X.sub.5X.sub.6X.sub.7EIX.sub.10X.sub.11LPNLX.sub.16RX.sub.18QYX.sub.21AFIX.sub.25X.sub.26LX.sub.28D. The present disclosure also relates to the use of such an IL-1R-I binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Disclosed are therapeutic payloads comprising p97 fragments coupled with active agents having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, to facilitate delivery of therapeutic or diagnostic agents across the BBB. The therapeutic payloads can be effective in the treatment of frontotemportal dementia (FTD). Methods of treating frontotemporal dementia (FTD) and pharmaceutical compositions are also disclosed.

A method for manufacturing a fraction comprising the proteins lactoferrin and/or lactoperoxidase from a source containing at least one of these proteins wherein the source is selected from the group consisting of milk, colostrum, acid or sweet whey, by means of a chromatographic separation process with a monolithic column having cation exchanger properties, wherein in the separation process a pH gradient or a combined pH and salt gradient elution is employed after loading the source to the column.

Further disclosed is a composition of matter comprising lactoferrin having a C value of >60% and A value of >1% or lactoperoxidase.

A method for manufacturing a fraction comprising the proteins lactoferrin and/or lactoperoxidase from a source containing at least one of these proteins wherein the source is selected from the group consisting of milk, colostrum, acid or sweet whey, by means of a chromatographic separation process with a monolithic column having cation exchanger properties, wherein in the separation process a pH gradient or a combined pH and salt gradient elution is employed after loading the source to the column.

Further disclosed is a composition of matter comprising lactoferrin having a C value of >60% and A value of >1% or lactoperoxidase.